

## 原著

1. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. *J Rheumatol* 24(2):328-332, 1997, Corresponding Author
2. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum tumor necrosis factor- $\alpha$  levels in patients with systemic sclerosis: association with pulmonary fibrosis. *J Rheumatol* 24(4):663-665, 1997, Corresponding Author
3. Hasegawa M, Takata M, Hatta N, Wakamatsu K, Ito S, Takehara K. Simultaneous measurement of serum 5-S-cysteinyl-dopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma. *Melanoma Res* 7(3):243-251, 1997
4. Hasegawa M, Sato S, Kikuchi K, Takehara K. Antigen specificity of antihistone antibodies in systemic sclerosis. *Ann Rheum Dis* 57(8):470-475, 1998, Corresponding Author
5. Takamatsu Y, Hasegawa M, Sato S, Takehara K. IL-13 production by peripheral blood mononuclear cells from patients with atopic dermatitis. *Dermatology* 196(4):377-381, 1998
6. Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. *J Rheumatol* 25(2):308-313, 1998, Corresponding Author
7. Tsutsui K, Hasegawa M, Takata M, Takehara K. Increased plasma granulocyte elastase levels in Behcet's disease. *J Rheumatol* 25(2):326-328, 1998
8. Sato S, Hasegawa M, Nagaoka T, Takamatsu Y, Yazawa N, Ihn H, Kikuchi K, Takehara K. Autoantibodies against calpastatin in sera from patients with systemic sclerosis. *J Rheumatol* 25(11):2135-2139, 1998
- ⑨. 長谷川稔, 全身性強皮症患者血中サイトカインレベル TNF- $\alpha$ , IL-2, IL-4, IL-6, IL-10, IL-13 と臨  
床病態及び免疫学的異常との相関. *金沢大学十全医学会雑誌* 107(2):118-128, 1998
10. 佐藤伸一, 平田昭夫, 西島千博, 長谷川稔, 永岡徹也, 竹原和彦. 全身性強皮症における腎血管抵抗の上昇に対するトランドラプリル製剤の効果. *臨床と研究* 76:172-174, 1999
11. Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1 $\alpha$  (MIP-1 $\alpha$ ) and MIP-1 $\beta$ ) in patients with systemic

sclerosis: MCP-1 and MIP-1 $\beta$  may be involved in the development of pulmonary fibrosis. *Clin Exp Immunol* 117(1): 159-165, 1999, Corresponding Author

12. Shimada Y, Sato S, Hasegawa M, Tedder TF, Takehara K. Elevated serum L-selectin levels and abnormal regulation of L-selectin expression on leukocytes in atopic dermatitis: soluble L-selectin levels indicate disease severity. *J Allergy Clin Immunol* 104(1): 163-168, 1999

13. Hasegawa M, Sato S, Ihn H, Takehara K. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. *Rheumatology (Oxford)* 38(7): 612-617, 1999

14. Nagaoka T, Kaburagi Y, Hamaguchi Y, Hasegawa M, Takehara K, Steeber DA, Tedder TF, Sato S. Delayed wound healing in the absence of intercellular adhesion molecule-1 or L-selectin expression. *Am J Pathol* 157(1): 237-247, 2000

15. Sato S, Hasegawa M, Ihn H, Kikuchi K, Takehara K. Clinical significance of antinuclear matrix antibody in serum from patients with anti-U1RNP antibody. *Arch Dermatol Res* 292(2-3): 55-59, 2000

16. Sato S, Nagaoka T, Hasegawa M, Nishijima C, Takehara K. Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis. *Dermatology* 200(3): 196-201, 2000

17. Sato S, Hasegawa M (co-first author), Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. *J Immunol* 165(11): 6635-6643, 2000

18. Sato S, Nagaoka T, Hasegawa M, Tamatani T, Nakanishi T, Takigawa M, Takehara K. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. *J Rheumatol* 27(1): 149-154, 2000

19. Nagaoka T, Sato S, Hasegawa M, Ihn H, Takehara K. Serum levels of soluble interleukin 6 receptor and soluble gp130 are elevated in patients with localized scleroderma. *J Rheumatol* 27(8): 1917-1921, 2000

20. Sato S, Hanakawa H, Hasegawa M, Nagaoka T, Hamaguchi Y, Nishijima C, Komatsu K, Hirata A, Takehara K. Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. *J Rheumatol* 27(12): 2838-2842, 2000

21. Hasegawa M, Fujimoto M, Poe JC, Steeber DA, Lowell CA, Tedder TF. A CD19-dependent signaling pathway regulates autoimmunity in Lyn-deficient mice. *J Immunol* 167(5): 2469-2478, 2001

※22. Hasegawa M, Fujimoto M, Poe JC, Steeber DA, Tedder TF. CD19 can regulate B lymphocyte signal

transduction independent of complement activation. *J Immunol* 167(6):3190-200.

23. Kaburagi Y, Shimada Y, Nagaoka T, Hasegawa M, Takehara K, Sato S. Enhanced production of CC-chemokines (RANTES, MCP-1, MIP-1 $\alpha$ , MIP-1 $\beta$ , and eotaxin) in patients with atopic dermatitis.

*Arch Dermatol Res* 293(7): 350-355, 2001

24. Shimada Y, Hasegawa M, Takehara K, Sato S. Elevated serum L-selectin levels and decreased L-selectin expression on CD8<sup>+</sup> lymphocytes in systemic sclerosis. *Clin Exp Immunol* 124(3): 474-479, 2001

25. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. *J Dermatol Sci* 27(2): 140-146, 2001

26. Sato S, Komura K, Hasegawa M, Fujimoto M, Takehara K. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc. *J Rheumatol* 28(11): 2460-2465, 2001

27. Fujimoto M, Poe JC, Hasegawa M, Tedder TF. CD19 amplification of B lymphocyte Ca<sup>2+</sup> responses: a role for Lyn sequestration in extinguishing negative regulation. *J Biol Chem* 276(48):44820-7, 2001

28. Nishijima C, Sato S, Hasegawa M, Nagaoka T, Hirata A, Komatsu K, Takehara K. Renal vascular damage in Japanese patients with systemic sclerosis. *Rheumatology (Oxford)* 40(4): 406-409, 2001

29. Sato S, Hamaguchi Y, Hasegawa M, Takehara K. Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. *Rheumatology (Oxford)* 40(10): 1135-1140, 2001

30. 稲沖真, 斉藤恵里子, 長谷川稔, 佐藤伸一, 竹原和彦. 全身性強皮症患者にみられる血清中インターロイキン6の増加に対するアルプロスタジルの抑制効果の検討. *Medical Postgraduates* 40(2): 146-149, 2002

31. 佐藤伸一, 小寺雅也, 藤井秀孝, 永岡徹也, 濱口儒人, 長谷川稔, 竹原和彦. プロスタグランジン<sub>12</sub>誘導体制剤であるベラプロストナトリウムの膠原病に伴う肺高血圧症に対する効果. *臨床と研究* 79:134-138, 2002

32. 長谷川稔, 佐藤伸一, 竹原和彦. 全身性強皮症の難治性皮膚潰瘍におけるフィブラストプレー (遺伝子組換えヒト塩基性線維芽細胞増殖因子) の使用経験. *臨床と研究* 79: 156-159, 2002

※33. Haas KM, Hasegawa M (co-first author), Steeber DA, Poe JC, Zabel MD, Bock CB, Karp DR, Briles DE, Weis JH, Tedder TF. Complement receptors CD21/35 link innate and protective immunity during

Streptococcus pneumoniae infection by regulating IgG3 antibody responses. *Immunity* 17(6):713-23, 2002

34. Hamaguchi Y, Nishizawa Y, Yasui M, Hasegawa M, Kaburagi Y, Komura K, Nagaoka T, Saito E, Shimada Y, Takehara K, Kadono T, Steeber DA, Tedder TF, Sato S. Intercellular adhesion molecule-1 and L-selectin regulate bleomycin-induced lung fibrosis. *Am J Pathol* 161(5): 1607-1618, 2002

35. Fujii H, Hasegawa M, Takehara K, Mukaida N, Sato S. Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T lymphocytes from patients with systemic sclerosis. *Clin Exp Immunol* 130(3): 548-556, 2002

36. Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, Nagaoka T, Takehara K, Tedder TF, Sato S. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. *J Clin Invest* 109(11): 1453-1462, 2002

37. Kaburagi Y, Hasegawa M, Nagaoka T, Shimada Y, Hamaguchi Y, Komura K, Saito E, Yanaba K, Takehara K, Kadono T, Steeber DA, Tedder TF, Sato S. The cutaneous reverse Arthus reaction requires intercellular adhesion molecule 1 and L-selectin expression. *J Immunol* 168(6): 2970-2978, 2002

38. Komura K, Sato S, Fujimoto M, Hasegawa M, Takehara K. Elevated levels of circulating CD44 in patients with systemic sclerosis: association with a milder subset. *Rheumatology (Oxford)* 41(10): 1149-1154, 2002

39. 佐藤伸一, 長谷川稔, 濱口儒人, 梁場広一, 竹原和彦. 全身性強皮症に合併したシェーグレン症候群に対する塩酸セビメリン (サリグレンカプセル) の臨床効果. *臨床と研究* 80:175-178, 2003

40. 長谷川稔, 佐藤伸一, 梁場広一, 小村一浩, 早川郁子, 濱口儒人, 竹原和彦. ステロイド内服中の膠原病患者における骨粗鬆症-エチドロネートの治療効果と安全性. *臨床と研究* 80: 1753-1756, 2003

41. Sato S, Fujimoto M, Hasegawa M, Takehara K. Antiphospholipid antibody in localised scleroderma. *Ann Rheum Dis* 62(8): 771-774, 2003

42. Hasegawa M, Sato S, Nagaoka T, Fujimoto M, Takehara K. Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. *Dermatology* 207(2): 141-147, 2003, Corresponding Author

43. Yanaba K, Hasegawa M, Hamaguchi Y, Fujimoto M, Takehara K, Sato S. Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis. *Clin Exp Rheumatol* 21(4): 429-436, 2003

44. Shimada Y, Hasegawa M, Kaburagi Y, Hamaguchi Y, Komura K, Saito E, Takehara K, Steeber DA, Tedder TF, Sato S. L-selectin or ICAM-1 deficiency reduces an immediate-type hypersensitivity response

- by preventing mast cell recruitment in repeated elicitation of contact hypersensitivity. *J Immunol* 170(8) : 4325–4334, 2003
45. Komura K, Hasegawa M, Hamaguchi Y, Saito E, Kaburagi Y, Yanaba K, Kawara S, Takehara K, Seki M, Steeber DA, Tedder TF, Sato S. Ultraviolet light exposure suppresses contact hypersensitivity by abrogating endothelial intercellular adhesion molecule-1 up-regulation at the elicitation site. *J Immunol* 171(6) : 2855–2862, 2003
46. Sato S, Hayakawa I, Hasegawa M, Fujimoto M, Takehara K. Functional blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. *J Invest Dermatol* 120(4) : 542–547, 2003
47. Furuse S, Fujii H, Kaburagi Y, Fujimoto M, Hasegawa M, Takehara K, Sato S. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene- $\alpha$  are elevated in patients with systemic sclerosis. *J Rheumatol* 30(7) : 1524–1528, 2003
48. Uchida J, Lee Y, Hasegawa M, Liang Y, Bradney A, Oliver JA, Bowen K, Steeber DA, Haas KM, Poe JC, Tedder TF. Mouse CD20 expression and function. *Int Immunol* 16(1) : 119–29, 2004
49. Asano N, Fujimoto M, Yazawa N, Shirasawa S, Hasegawa M, Okochi H, Tamaki K, Tedder TF, Sato S. B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. *Am J Pathol* 165(2) : 641–650, 2004
50. Poe JC, Fujimoto Y, Hasegawa M, Haas KM, Miller AS, Sanford IG, Bock CB, Fujimoto M, Tedder TF. CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. *Nat Immunol* 5(10) : 1078–87, 2004
51. Hasegawa M, Sato S, Yanaba K, Komura K, Yamazaki M, Takehara K. Autoantibodies against phosphatidylserine-prothrombin complex in patients with systemic sclerosis. *Ann Rheum Dis* 63(11) : 1514–1517, 2004, Corresponding Author
52. Hasegawa M, Sato S, Takehara K. Augmented production of transforming growth factor- $\beta$  by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. *Arch Dermatol Res* 296(2) : 89–93, 2004, Corresponding Author
53. Hayakawa I, Hasegawa M, Takehara K, Sato S. Anti-DNA topoisomerase II $\alpha$  autoantibodies in localized scleroderma. *Arthritis Rheum* 50(1) : 227–232, 2004
54. Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. *Arthritis Rheum* 50(6) : 1918–1927, 2004

55. Sato S, Kodera M, Hasegawa M, Fujimoto M, Takehara K. Antinucleosome antibody is a major autoantibody in localized scleroderma. *Br J Dermatol* 151(6): 1182-1188, 2004
56. Nishijima C, Hayakawa I, Matsushita T, Komura K, Hasegawa M, Takehara K, Sato S. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. *Clin Exp Immunol* 138(2): 357-363, 2004
57. Echigo T, Hasegawa M, Shimada Y, Takehara K, Sato S. Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: possible contribution to skin inflammation. *J Allergy Clin Immunol* 113(5): 940-948, 2004
58. Fujii H, Shimada Y, Hasegawa M, Takehara K, Sato S. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. *J Dermatol Sci* 35(1): 43-51, 2004
59. Nagai M, Hasegawa M, Takehara K, Sato S. Novel autoantibody to Cu/Zn superoxide dismutase in patients with localized scleroderma. *J Invest Dermatol* 122(3): 594-601, 2004.
60. Komura K, Sato S, Hasegawa M, Fujimoto M, Takehara K. Elevated circulating CD40L concentrations in patients with systemic sclerosis. *J Rheumatol* 31(3): 514-519, 2004.
61. Sato S, Fujimoto M, Hasegawa M, Komura K, Yanaba K, Hayakawa I, Matsushita T, Takehara K. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. *Rheumatology (Oxford)* 43(10): 1261-1266, 2004
62. Yanaba K, Hasegawa M, Takehara K, Sato S. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. *J Rheumatol* 31(6): 1112-1120, 2004
63. 小村一浩, 佐藤伸一, 田中千洋, 築場広一, 長谷川稔, 安井正英, 竹原和彦. 全身性強皮症に合併した間質性肺炎に対する, ステロイドを併用したシクロフォスファミドパルス療法. *日本皮膚科学会雑誌* 114(14): 2327-2333, 2004
64. 小寺雅也, 長谷川稔, 松下貴史, 築場広一, 早川郁子, 小村一浩, 西島千博, 竹原和彦, 佐藤伸一. 全身性強皮症患者における可溶性ICAM-1濃度に対するペリンドプリルの効果. *臨床と研究* 82(2): 364-366, 2005
65. 西島千博, 長谷川稔, 竹原和彦, 佐藤伸一. 全身性強皮症患者におけるSodium Rabeprazoleの長期的臨床効果および安全性. *臨床と研究* 82(2): 375-378, 2005
66. Hasegawa M, Sato S, Echigo T, Hamaguchi Y, Yasui M, Takehara K: Up regulated expression of fractalkine/CX<sub>3</sub>CL1 and CX<sub>3</sub>CR1 in patients with systemic sclerosis. *Ann Rheum Dis* 64(1): 21-28,

2005, Corresponding Author

67. Hayakawa I, Hasegawa M, Takehara K, Sato S. Anti-DNA topoisomerase II $\alpha$  autoantibodies in systemic sclerosis. *Arch Dermatol Res* 297(4): 180-183, 2005

68. Koder M, Hasegawa M, Komura K, Yanaba K, Takehara K, Sato S. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. *Arthritis Rheum* 52(9): 2889-2896, 2005

69. Horikawa M, Hasegawa M, Komura K, Hayakawa I, Yanaba K, Takehara K, Sato S: Abnormal natural killer cell function in systemic sclerosis: altered cytokine production and defective killing activity. *J Invest Dermatol* 125(4): 731-737, 2005

70. Koder M, Hayakawa I, Komura K, Yanaba K, Hasegawa M, Takehara K, Sato S. Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations. *J Rheumatol* 32(4): 629-636, 2005

71. Hayakawa I, Hasegawa M, Matsushita T, Yanaba K, Koder M, Komura K, Takehara K, Sato S. Increased cutaneous T cell-attracting chemokine levels in sera from patients with systemic sclerosis. *Rheumatology (Oxford)* 44(7): 873-878, 2005, Corresponding Author

72. 河嶋洋平, 山崎雅英, 森下英理子, 朝倉英策, 長谷川稔, 大竹茂樹. 異なる疾患群における IgG 型抗プロトロンビン抗体測定キット 2 社間の測定値の乖離. *日本血栓止血学会誌* 16(4): 378-385, 2005

73. 山田瑞貴, 長谷川稔, 竹原和彦, 佐藤伸一. 全身性強皮症患者における可溶性 ICAM-1 濃度に対する lipo prostaglandin E1 の効果 (第 2 報) 間歇投与による持続効果の検討. *臨床と研究* 83(5): 778-780, 2006

74. Matsushita T, Fujimoto M, Hasegawa M, Komura K, Takehara K, Tedder TF, Sato S. Inhibitory role of CD19 in the progression of experimental autoimmune encephalomyelitis by regulating cytokine response. *Am J Pathol* 168(3): 812-821, 2006

75. Horikawa M, Fujimoto M, Hasegawa M, Matsushita T, Hamaguchi Y, Kawasuji A, Matsushita Y, Fujita T, Ogawa F, Takehara K, Steeber DA, Sato S. E- and P-selectins synergistically inhibit bleomycin-induced pulmonary fibrosis. *Am J Pathol* 169(3): 740-749, 2006

※76. Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, Matsushita T, Matsushita Y, Horikawa M, Komura K, Takehara K, Sato S, Tedder TF. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. *Am J Pathol* 169(3): 954-966, 2006

77. Nakajima K, Kawano M, Hasegawa M, Taki J, Fujimoto M, Takehara K, Tonami N. Myocardial damages

in systemic sclerosis detected by gated myocardial perfusion SPECT and sympathetic imaging. *Circ J* 70 (11):1481-7, 2006

78. Yanaba K, Komura K, Koderu T, Matsushita M, Hasegawa M, Takehara K, Sato S. Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. *Ann Rheum Dis* 65(1): 124-126, 2006

79. Echigo T, Hasegawa M, Shimada Y, Inaoki M, Takehara K, Sato S. Both Th1 and Th2 chemokines are elevated in sera of patients with autoimmune blistering diseases. *Arch Dermatol Res* 298(1): 38-45, 2006, Corresponding Author

80. Matsushita T, Hasegawa M, Yanaba K, Koderu M, Takehara K, Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. *Arthritis Rheum* 54(1): 192-201, 2006

81. Yamada M, Yanaba K, Hasegawa M, Matsushita Y, Horikawa M, Komura K, Matsushita T, Kawasuji A, Fujita T, Takehara K, Steeber DA, Tedder TF, Sato S. Regulation of local and metastatic host-mediated anti-tumour mechanisms by L-selectin and intercellular adhesion molecule-1. *Clin Exp Immunol* 143(2): 216-227, 2006

82. Fujimoto M, Hasegawa M, Hamaguchi Y, Komura K, Matsushita T, Yanaba K, Koderu M, Takehara K, Sato S. A clue for telangiectasis in systemic sclerosis: elevated serum soluble endoglin levels in patients with the limited cutaneous form of the disease. *Dermatology* 213(2): 88-92, 2006

83. Hasegawa M, Fujimoto M, Hayakawa I, Matsushita T, Nishijima C, Yamazaki M, Takehara K, Sato S. Anti-phosphatidylserine-prothrombin complex antibodies in patients with localized scleroderma. *Clin Exp Rheumatol* 24(1): 19-24, 2006, Corresponding Author

84. Inaoki M, Echigo T, Hayashi H, Nagaoka T, Hasegawa M, Takehara K, Fujimoto W, Tedder TF, Sato S. Decreased expression levels of CD22 and L-selectin on peripheral blood B lymphocytes from patients with bullous pemphigoid. *J Autoimmun* 27(3): 196-202, 2006

85. Kawasuji A, Hasegawa M, Horikawa M, Fujita T, Matsushita Y, Matsushita T, Fujimoto M, Steeber DA, Tedder TF, Takehara K, Sato S. L-selectin and intercellular adhesion molecule-1 regulate the development of Concanavalin A-induced liver injury. *J Leukoc Biol* 79(4): 696-705, 2006, Corresponding Author

86. Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with



spontaneous regression of skin sclerosis. *J Rheumatol* 33(2): 275-284, 2006

87. Mugii N, Hasegawa M, Matsushita T, Kondo M, Orito H, Yanaba K, Komura K, Hayakawa I, Hamaguchi Y, Ikuta M, Tachino K, Fujimoto M, Takehara K, Sato S. The efficacy of self-administered stretching for finger joint motion in Japanese patients with systemic sclerosis. *J Rheumatol* 33(8): 1586-1592, 2006, Corresponding Author

88. Ogawa F, Shimizu K, Muroi E, Hara T, Hasegawa M, Takehara K, Sato S. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. *Rheumatology (Oxford)* 45(7): 815-818, 2006

89. Matsushita T, Hasegawa M, Matsushita Y, Echigo T, Wayaku T, Horikawa M, Ogawa F, Takehara K, Sato S. Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases. *Exp Dermatol* 16(2): 87-93, 2007

90. 玉置邦彦, 佐伯秀久, 門野岳史, 佐藤伸一, 八田尚人, 長谷川稔, 白崎文朗, 島田由佳, 森田礼時, 西島千博, 越後岳士, 山田瑞貴, 大石直人, 中条園子, 富田育代, 平野貴士, 田中千洋, 竹原和彦, 尾藤利憲, 福永淳, 堀川達弥, 梅田二郎, 森田博子, 西野洋, 岡田明子, 片岡葉子, 秋永良也, 占部和敬, 師井洋一, 国場尚志, 今福信一, 幸田太, 中原剛士, 深川修司, 古江増隆. アトピー性皮膚炎の病勢指標としての TARC/CCL17 値についての臨床的検討. *日本皮膚科学会雑誌* 116(1): 27-39, 2006.

91. Shimada Y, Suzuki M, Shirasaki F, Saito E, Sogo K, Hasegawa M, Takehara K, Phromjai J, Chuhjo H, Shiraki K. Genital herpes due to acyclovir-sensitive herpes simplex virus caused secondary and recurrent herpetic whitlows due to thymidine kinase-deficient/temperature-sensitive virus. *J Med Virol* 79(11):1731-40, 2007

92. Fujita T, Fujimoto M, Matsushita T, Shimada Y, Hasegawa M, Kuwano Y, Ogawa F, Takehara K, Sato S. Phase-dependent roles of E-selectin during chronic contact hypersensitivity responses. *Am J Pathol* 170(5): 1649-1658, 2007

93. Echigo T, Hasegawa M, Inaoki M, Yamazaki M, Sato S, Takehara K. Antiphospholipid antibodies in patients with autoimmune blistering disease. *J Am Acad Dermatol* 57(3): 397-400, 2007, Corresponding Author

※94. Matsushita Y, Hasegawa M, Matsushita T, Fujimoto M, Horikawa M, Fujita T, Kawasuji A, Ogawa F, Steeber DA, Tedder TF, Takehara K, Sato S. Intercellular adhesion molecule-1 deficiency attenuates the development of skin fibrosis in tight-skin mice. *J Immunol* 179(1): 698-707, 2007, Corresponding Author

95. Matsushita T, Fujimoto M, Hasegawa M, Matsushita Y, Komura K, Ogawa F, Watanabe R, Takehara

- K, Sato S. BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice. *J Invest Dermatol* 127(12): 2772-2780, 2007
96. Yukami T, Hasegawa M, Matsushita Y, Fujita T, Matsushita T, Horikawa M, Komura K, Yanaba K, Hamaguchi Y, Nagaoka T, Ogawa F, Fujimoto M, Steeber DA, Tedder TF, Takehara K, Sato S. Endothelial selectins regulate skin wound healing in cooperation with L-selectin and ICAM-1. *J Leukoc Biol* 82(3): 519-531, 2007, Corresponding Author
97. Orito H, Fujimoto M, Ishiura N, Yanaba K, Matsushita T, Hasegawa M, Ogawa F, Takehara K, Sato S. Intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 cooperatively contribute to the cutaneous Arthus reaction. *J Leukoc Biol* 81(5): 1197-1204, 2007
98. Komura K, Fujimoto M, Matsushita T, Yanaba K, Koderia M, Kawasuji A, Hasegawa M, Takehara K, Sato S. Increased serum soluble CD40 levels in patients with systemic sclerosis. *J Rheumatol* 34(2): 353-358, 2007
99. Matsushita T, Hasegawa M, Fujimoto M, Hamaguchi Y, Komura K, Hirano T, Horikawa M, Kondo M, Orito H, Kaji K, Saito Y, Matsushita Y, Kawara S, Yasui M, Seishima M, Ozaki S, Kuwana M, Ogawa F, Sato S, Takehara K. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. *J Rheumatol* 34(5): 1012-1018, 2007, Corresponding Author
100. Matsushita T, Fujimoto M, Hasegawa M, Tanaka C, Kumada S, Ogawa F, Takehara K, Sato S. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. *J Rheumatol* 34(10): 2056-2062, 2007
101. Wayaku T, Hasegawa M, Kaji K, Kondo M, Saito Y, Orito H, Horikawa M, Matsushita T, Komura K, Hayakawa I, Hamaguchi Y, Ogawa F, Fujimoto M, Takehara K, Sato S. Antigen specificity of antihistone antibodies in connective tissue disease patients with anti-U1RNP antibodies. *Rheumatol Int* 28(2): 113-119, 2007, Corresponding Author
102. Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K, Matsushita T, Orito H, Hamaguchi Y, Yanaba K, Itoh M, Asano Y, Seishima M, Ogawa F, Sato S, Takehara K. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. *Rheumatology (Oxford)* 46(1): 25-28, 2007
103. Iwata Y, Ogawa F, Komura K, Muroi E, Hara T, Shimizu K, Hasegawa M, Fujimoto M, Tomita Y, Sato S. Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress. *Rheumatology (Oxford)* 46(5): 790-795, 2007
104. Hitomi Y, Tsuchiya N, Hasegawa M, Fujimoto M, Takehara K, Tokunaga K, Sato S. Association of

CD22 gene polymorphism with susceptibility to limited cutaneous systemic sclerosis. *Tissue Antigens* 69(3): 242-249, 2007

105. 荒井美奈子, 白崎文朗, 長谷川稔, 竹原和彦. 当科で経験した成人発症 Still 病 15 例の検討. *日本皮膚科学会雑誌* 117(14):2471-2478, 2007

106. Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Tedder TF, Sato S. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. *Am J Pathol* 172(6): 1650-1663, 2008

107. Komura K, Fujimoto M, Yanaba K, Matsushita T, Matsushita Y, Horikawa M, Ogawa F, Shimizu K, Hasegawa M, Takehara K, Sato S: Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse. *Ann Rheum Dis* 67(6): 867-872, 2008

108. Ogawa F, Shimizu K, Hara T, Muroi E, Hasegawa M, Takehara K, Sato S. Serum levels of heat shock protein 70, a biomarker of cellular stress, are elevated in patients with systemic sclerosis: association with fibrosis and vascular damage. *Clin Exp Rheumatol* 26(4): 659-662, 2008

109. Hikami K, Ehara Y, Hasegawa M, Fujimoto M, Matsushita M, Oka T, Takehara K, Sato S, Tokunaga K, Tsuchiya N. Association of IL-10 receptor 2 (IL10RB) SNP with systemic sclerosis. *Biochem Biophys Res Commun* 373(3): 403-407, 2008

110. Hamaguchi Y, Hasegawa M, Fujimoto M, Matsushita T, Komura K, Kaji K, Kondo M, Nishijima C, Hayakawa I, Ogawa F, Kuwana M, Takehara K, Sato S. The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. *Br J Dermatol* 158(3): 487-495, 2008

111. Matsushita T, Fujimoto M, Echigo T, Matsushita Y, Shimada Y, Hasegawa M, Takehara K, Sato S. Elevated serum levels of APRIL, but not BAFF, in patients with atopic dermatitis. *Exp Dermatol* 17(3): 197-202, 2008

112. Tomimura S, Ogawa F, Iwata Y, Komura K, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S. Autoantibodies against matrix metalloproteinase-1 in patients with localized scleroderma. *J Dermatol Sci* 52(1): 47-54, 2008

※113. Saito Y, Hasegawa M, Fujimoto M, Matsushita T, Horikawa M, Takenaka M, Ogawa F, Sugama J, Steeber DA, Sato S, Takehara K. The loss of MCP-1 attenuates cutaneous ischemia-reperfusion injury in a mouse model of pressure ulcer. *J Invest Dermatol* 128(7):1838-1851, 2008, Corresponding Author

114. Komura K, Fujimoto M, Hasegawa M, Ogawa F, Hara T, Muroi E, Takehara K, Sato S. Increased serum interleukin 23 in patients with systemic sclerosis. *J Rheumatol* 35(1): 120-125, 2008

115. Hara T, Ogawa F, Muroi E, Komura K, Takenaka M, Hasegawa M, Fujimoto M, Sato S. Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis. *J Rheumatol* 35(3): 451-457, 2008
116. Muroi E, Ogawa F, Shimizu K, Komura K, Hasegawa M, Fujimoto M, Sato S. Elevation of serum lymphotactin levels in patients with systemic sclerosis. *J Rheumatol* 35(5): 834-838, 2008
117. Yoshizaki A, Iwata Y, Komura K, Hara T, Ogawa F, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S. Clinical significance of serum hyaluronan levels in systemic sclerosis: association with disease severity. *J Rheumatol* 35(9): 1825-1829, 2008
118. Komura K, Yoshizaki A, Koderu M, Iwata Y, Ogawa F, Shimizu K, Wayaku T, Yukami T, Murata M, Hasegawa M, Fujimoto M, Takehara K, Sato S. Increased serum soluble OX40 in patients with systemic sclerosis. *J Rheumatol* 35(12):2359-2362, 2008
119. Hamaguchi Y, Fujimoto M, Matsushita T, Hasegawa M, Takehara K, Sato S. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis. *J Rheumatol* 35(12): 2363-2371, 2008
120. Yamaoka T, Ogawa F, Muroi E, Hara T, Komura K, Iwata Y, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S. Autoantibody against a protease domain of caspase-8 in patients with systemic sclerosis. *Clin Exp Rheumatol* 26(6):998-1004, 2008
121. 村田真希, 加治賢三, 濱口儒人, 長谷川稔, 藤本学, 竹原和彦, 桑名正隆. 当科における抗 RNA ポリメラーゼ抗体陽性全身性強皮症の臨床的特徴. *皮膚科の臨床* 50(3): 323-327, 2008
122. 栗山喬之, 田邊信宏, 佐藤徹, 佐地勉, 中山智孝, 竹原和彦, 長谷川稔, 渡邊裕司, 竹内和彦, 山田典一, 太田覚史, 中野起, 原田明久. 肺動脈性肺高血圧症に対するシルデナフィルクエン酸塩の使用成績. *臨床医薬* 24(4): 275-287, 2008
123. Mugii N, Hasegawa M, Hamaguchi Y, Tanaka C, Kaji K, Komura K, Ueda-Hayakawa I, Horie S, Ikuta M, Tachino K, Ogawa F, Sato S, Fujimoto M, Takehara K. Reduced red blood cell velocity in nail-fold capillaries as a sensitive and specific indicator of microcirculation injury in systemic sclerosis. *Rheumatology (Oxford)* 48(6):696-703, 2009, Corresponding Author
124. Ishii T, Fujita T, Matsushita T, Yanaba K, Hasegawa M, Nakashima H, Ogawa F, Shimizu K, Takehara K, Tedder TF, Sato S, Fujimoto M. Establishment of experimental eosinophilic vasculitis by IgE-mediated cutaneous reverse passive Arthus reaction. *Am J Pathol* 174(6):2225-33, 2009
125. Ito I, Kawaguchi Y, Kawasaki A, Hasegawa M, Ohashi J, Hikami K, Kawamoto M, Fujimoto M, Takehara K, Sato S, Hara M, Tsuchiya N. Association of a functional polymorphism in the IRF5 region with

- systemic sclerosis in a Japanese population. *Arthritis Rheum* 60(6):1845–50, 2009
126. Kuwatsuka Y, Ogawa F, Iwata Y, Komura K, Muroi E, Hara T, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S. Decreased levels of autoantibody against histone deacetylase 3 in patients with systemic sclerosis. *Autoimmunity* 42(2):120–5, 2009
127. Yoshizaki A, Komura K, Iwata Y, Ogawa F, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S. Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. *J Clin Immunol* 29(2):180–9, 2009
128. Hara T, Ogawa F, Yanaba K, Iwata Y, Muroi E, Komura K, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S. Elevated serum levels of polymorphonuclear neutrophilic leukocyte elastase in systemic sclerosis: association with pulmonary fibrosis. *J Rheumatol* 36(1):99–105, 2009
129. Iwata Y, Yoshizaki A, Ogawa F, Komura K, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Takehara K, Sato S. Increased serum pentraxin3 in patients with systemic sclerosis. *J Rheumatol* 36(5):976–83, 2009
130. Tomita H, Iwata Y, Ogawa F, Komura K, Shimizu K, Yoshizaki A, Hara T, Muroi E, Yanaba K, Bae SJ, Takenaka M, Hasegawa M, Fujimoto M, Sato S. P-selectin glycoprotein ligand-1 contributes to wound healing. *J Invest Dermatol* 129(8):2059–67, 2009
131. Iwata Y, Yoshizaki A, Komura K, Shimizu K, Ogawa F, Hara T, Muroi T, Bae S, Takenaka M, Yukami T, Hasegawa M, Fujimoto M, Tomita Y, Tedder TF, Sato S. CD19, a response regulator of B lymphocytes, regulates wound healing through hyaluronan-induced TLR4 signaling. *Am J Pathol* 175(2):649–660, 2009
132. Kawaguchi Y, Ota Y, Kawamoto M, Ito I, Tsuchiya N, Sugiura T, Katsumata Y, Soejima M, Sato S, Hasegawa M, Fujimoto M, Takehara K, Kuwana M, Yamanaka H, Hara M. Association study of a polymorphism of the CTGF gene and susceptibility to systemic sclerosis in the Japanese population. *Ann Rheum Dis* 2009
133. Komura K, Iwata Y, Ogawa F, Yoshizaki A, Yamaoka T, Akiyama Y, Hara T, Hasegawa M, Fujimoto M, Sato S. Low zone tolerance requires ICAM-1 expression to limit contact hypersensitivity elicitation. *J Invest Dermatol* 129(11):2661–7, 2009
134. Yanaba K, Yoshizaki A, Muroi E, Hara T, Ogawa F, Usui A, Hasegawa M, Fujimoto M, Takehara K, Sato S. Elevated circulating TWEAK levels in systemic sclerosis: association with lower frequency of pulmonary fibrosis. *J Rheumatol* 36(8):1657–62, 2009
135. Yanaba K, Muroi E, Yoshizaki A, Hara T, Ogawa F, Shimizu K, Yozaki M, Hasegawa M, Fujimoto M, Takehara K, Sato S. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in

patients with systemic sclerosis. *J Rheumatol* 36(9):1917–23, 2009

136. Akiyama Y, Ogawa F, Iwata Y, Komura K, Hara T, Muroi E, Bae SJ, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S. Autoantibody against activating transcription factor-2 in patients with systemic sclerosis. *Clin Exp Rheumatol* 27(5):751–7, 2009

※137. Hasegawa M, Matsushita Y, Horikawa M, Higashi K, Tomigahara Y, Kaneko H, Shirasaki F, Fujimoto M, Takehara K, Sato S. A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mice models of systemic sclerosis. *Arthritis Rheum* 60(11): 3465–75, 2009, Corresponding Author

138. Tsuchiya N, Kawasaki A, Hasegawa M, Fujimoto M, Takehara K, Kawaguchi Y, Kawamoto M, Hara M, Sato S. Association of STAT4 polymorphism with systemic sclerosis in a Japanese population. *Ann Rheum Dis* 68(8), 1375–1376, 2009

139. 麦井直樹, 西悦子, 堀江翔, 八幡徹太郎, 長谷川稔, 生田宗博, 井上克己, 染矢富士子. 全身性強皮症患者における6分間歩行テストの検討. *総合リハビリテーション* 38(6): 571–576, 2008

140. Ogawa F, Shimizu K, Hara T, Muroi E, Komura K, Takenaka M, Hasegawa M, Fujimoto M, Takehara K, Sato S. Autoantibody against one of the antioxidant repair enzymes, methionine sulfoxide reductase A, in systemic sclerosis: association with pulmonary fibrosis and vascular damage. *Arch Dermatol Res* 302(1):27–35, 2010

141. Okazaki S, Ogawa F, Iwata Y, Hara T, Muroi E, Komura K, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S. Autoantibody against caspase-3, an executioner of apoptosis, in patients with systemic sclerosis. *Rheumatol Int* 30(7):871–8, 2010

142. Yanaba K, Yoshizaki A, Muroi E, Hara T, Ogawa F, Shimizu K, Hasegawa M, Fujimoto M, Takehara K, Sato S. CCL13 is a promising diagnostic marker for systemic sclerosis. *Br J Dermatol* 162(2):332–6, 2010

143. Odaka M, Hasegawa M, Hamaguchi Y, Ishiura N, Kumada S, Matsushita T, Komura K, Sato S, Takehara K, Fujimoto M. Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis. *Clin Exp Immunol* 159(2):176–84, 2010

144. Hara T, Shimizu K, Ogawa F, Yanaba K, Iwata Y, Muroi E, Takenaka M, Komura K, Hasegawa M, Fujimoto M, Sato S. Platelets control leukocyte recruitment in a murine model of cutaneous arthus reaction. *Am J Pathol* 176(1):259–69, 2010

145. Ito I, Kawaguchi Y, Kawasaki A, Hasegawa M, Ohashi J, Kawamoto M, Fujimoto M, Takehara K, Sato S, Hara M, Tsuchiya N. Association of FAM167A (C8orf13) – BLK region with systemic sclerosis.

*Arthritis Rheum* 62(3): 890-5, 2010

146. Tomita H, Ogawa F, Hara T, Yanaba K, Iwata Y, Muroi E, Yoshizaki A, Komura K, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S. Elevated serum concentrations of triggering receptor expressed on myeloid cells-1 in diffuse cutaneous systemic sclerosis: association with severity of pulmonary fibrosis. *J Rheumatol* 37(4): 787-91, 2010

147. Ogawa A, Yoshizaki A, Yanaba K, Ogawa F, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Tedder TF, Sato S. The differential role of L-Selectin and ICAM-1 in Th1-Type and Th2-Type contact hypersensitivity. *J Invest Dermatol* 130(6):1558-70, 2010.

※148. Tanaka C, Fujimoto M, Hamaguchi Y, Sato S, Takehara K, Hasegawa M. Inducible costimulator ligand (ICOSL) regulates bleomycin-induced lung and skin fibrosis independently of the ICOS-ICOSL pathway. *Arthritis Rheum* 62(6):1723-32, 2010, Corresponding Author

149. Yoshizaki A, Yanaba K, Yoshizaki A, Iwata Y, Komura K, Ogawa F, Takenaka M, Shimizu K, Asano Y, Hasegawa M, Fujimoto M, Sato S. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. *Arthritis Rheum* 62(8):2476-87, 2010

150. Yoshizaki A, Yanaba K, Iwata Y, Komura K, Ogawa A, Akiyama Y, Muroi E, Hara T, Ogawa F, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Tedder TF, Sato S. Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. *J Immunol* 185(4):2502-15, 2010

151. Ueda-Hayakawa I, Hasegawa M, Kumada S, Tanaka C, Komura K, Hamaguchi Y, Takehara K, Fujimoto M. Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis. *Rheumatology (Oxford)* 49(11):2135-9, 2010.

152. 井上雄二、長谷川稔、前川武雄、レパヴー・アンドレ、浅野善英、安部正敏、石井貴之、伊藤孝明、爲政大幾、今福信一、入澤亮吉、大塚正樹、大塚幹夫、小川文秀、門野岳史、小寺雅也、川上民裕、川口雅一、久木野竜一、幸野 健、境 恵祐、高原正和、谷岡未樹、中西健史、中村泰大、橋本 彰、林 昌浩、藤本 学、藤原 浩、松尾光馬、間所直樹、山崎 修、吉野雄一郎、立花隆夫、尹 浩信。創傷・熱傷ガイドライン委員会報告-1：創傷一般。 *日皮会誌* 121: 1539-9, 2011

153. 立花隆夫、今福信一、入澤亮吉、大塚正樹、門野岳史、藤原 浩、浅野善英、安部正敏、石井貴之、爲政大幾、伊藤孝明、井上雄二、大塚幹夫、小川文秀、小寺雅也、川上民裕、川口雅一、久木野竜一、幸野 健、境 恵祐、高原正和、谷岡未樹、中西健史、中村泰大、橋本 彰、長谷川稔、林 昌浩、藤本 学、前川武雄、松尾光馬、間所直樹、山崎 修、吉野雄一郎、レパヴー・アンドレ、尹 浩信。創傷・熱傷ガイドライン委員会報告-2：褥瘡診療ガイドライン。 *日皮会誌* 121: 1791-839, 2011

154. 爲政大幾、安部正敏、中西健史、松尾光馬、山崎 修、浅野善英、石井貴之、伊藤孝明、井上雄二、今福信一、入澤亮吉、大塚正樹、大塚幹夫、小川文秀、門野岳史、小寺雅也、川上民裕、川口雅一、久木野竜一、幸野 健、境 恵祐、高原正和、谷岡未樹、中村泰大、橋本 彰、長谷川稔、林 昌浩、藤本 学、藤原 浩、前川武雄、間所直樹、吉野雄一郎、レパヴー・アンドレ、立花隆夫、尹 浩信. 創傷・熱傷ガイドライン委員会報告-3: 糖尿病性潰瘍・壊疽ガイドライン. *日皮会誌* 121: 1997-2035, 2011
155. 藤本 学、浅野善英、石井貴之、小川文秀、川上民裕、小寺雅也、安部正敏、爲政大幾、井上雄二、伊藤孝明、今福信一、入澤亮吉、大塚正樹、大塚幹夫、門野岳史、川口雅一、久木野竜一、幸野 健、境 恵祐、高原正和、谷岡未樹、中西健史、中村泰大、橋本 彰、長谷川稔、林 昌浩、藤原 浩、前川武雄、松尾光馬、間所直樹、山崎 修、吉野雄一郎、レパヴー・アンドレ、立花隆夫、尹 浩信. 創傷・熱傷ガイドライン委員会報告-4: 膠原病・血管炎にともなう皮膚潰瘍診療ガイドライン. *日皮会誌* 121: 2187-223, 2011
156. 伊藤孝明、久木野竜一、高原正和、谷岡未樹、中村泰大、浅野善英、安部正敏、石井貴之、爲政大幾、井上雄二、今福信一、入澤亮吉、大塚正樹、大塚幹夫、小川文秀、門野岳史、小寺雅也、川上民裕、川口雅一、幸野 健、境 恵祐、中西健史、橋本 彰、長谷川稔、林 昌浩、藤本 学、藤原 浩、前川武雄、松尾光馬、間所直樹、山崎 修、レパヴー・アンドレ、吉野雄一郎、立花隆夫、尹 浩信. 創傷・熱傷ガイドライン委員会報告-5: 下腿潰瘍・下肢静脈瘤診療ガイドライン. *日皮会誌* 121: 2431-48, 2011
157. 吉野雄一郎、大塚幹夫、川口雅一、境 恵祐、橋本 彰、林 昌浩、間所直樹、浅野善英、安部正敏、石井貴之、伊藤孝明、爲政大幾、井上雄二、今福信一、入澤亮吉、大塚正樹、小川文秀、門野岳史、小寺雅也、川上民裕、久木野竜一、幸野 健、高原正和、谷岡未樹、中西健史、中村泰大、長谷川稔、藤本 学、藤原 浩、前川武雄、松尾光馬、山崎 修、レパヴー・アンドレ、立花隆夫、尹 浩信. 創傷・熱傷ガイドライン委員会報告-6: 熱傷診療ガイドライン. *日皮会誌* 121: 3279-306, 2011
158. Yoshizaki A, Yanaba K, Iwata Y, Komura K, Ogawa A, Muroi E, Ogawa F, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S. Elevated serum interleukin-27 levels in patients with systemic sclerosis: association with T cell, B cell and fibroblast activation. *Ann Rheum Dis* 70(1):194-200, 2011
159. Hasegawa M, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K, Sato S. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. *Clin Rheumatol* 30(2):231-7, 2011, Corresponding Author
160. Nakajima K, Matsuo S, Hasegawa M, Kinuya S, Takehara K. Identification of myocardial damage in systemic sclerosis: a nuclear cardiology approach. *Int J Rheumatol* pii 496509, 2010 (on-line Journal)
161. Hasegawa M, Fujimoto M, Hamaguchi Y, Matsushita T, Inoue K, Sato S, Takehara K. Use of Serum Clara Cell 16-kDa (CC16) Levels as a potential indicator of active pulmonary fibrosis in systemic



sclerosis. *J Rheumatol* 38 (5) :877–84, 2011, Corresponding Author

162. Nakajima K, Hasegawa M, Inaki A, Wakabayashi H, Hosoya T, Takehara K, Kinuya S. Esophageal transit study using a sliding sum image: application to patients with probable and definite systemic sclerosis. *Ann Nucl Med* 25 (5) :325–31, 2011

163. Mugii N, Hasegawa M, Matsushita T, Hamaguchi Y, Horie S, Yahata T, Inoue K, Someya F, Fujimoto M, Takehara K. Association between nail-fold capillary findings and disease activity in dermatomyositis. *Rheumatology (Oxford)* 50 (6) :1091–8, 2011, Corresponding Author

164. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, Komura K, Nakamura M, Kodera M, Suga N, Higashi A, Ogusu K, Tsutsui K, Furusaki A, Tanabe H, Sasaoka S, Muro Y, Yoshikawa M, Ishiguro N, Ayano M, Muroi E, Fujikawa K, Umeda Y, Kawase M, Mabuchi E, Asano Y, Sodemoto K, Seishima M, Yamada H, Sato S, Takehara K, Fujimoto M. Clinical correlations With dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. *Arch Dermatol* 147 (4) :391–8, 2011

165. Saito S, Nakayama T, Hashimoto N, Miyata Y, Egashira K, Nakao N, Nishiwaki S, Hasegawa M, Hasegawa Y, Naoe T. Mesenchymal stem cells stably transduced with a dominant negative inhibitor of GCL2 greatly attenuate bleomycin-induced lung damage. *Am J Pathol* 179 (3) :1088–94, 2011

※166. Maeda S, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K, Hasegawa M. Inducible costimulator (ICOS) –ICOS ligand signaling has pivotal roles in skin wound healing via cytokine production. *Am J Pathol* 179 (5) :2360–9, 2011, Corresponding Author

167. Hasegawa M, Asano Y, Endo H, Fujimoto M, Goto D, Ihn H, Inoue K, Ishikawa O, Kawaguchi Y, Kuwana M, Muro Y, Ogawa F, Sasaki T, Takahashi H, Tanaka S, Takehara K, Sato S. Investigation of prognostic factors for skin sclerosis and lung function in Japanese patients with early systemic sclerosis: a multicentre prospective observational study. *Rheumatology (Oxford)* 51 (1) :129–33, 2012, Corresponding Author

※168. Nakasone Y, Fujimoto M, Matsushita T, Hamaguchi Y, Huu DL, Yanaba M, Sato S, Takehara K, Hasegawa M. Host-derived MCP-1 and MIP-1a regulate protective anti-tumor immunity to localized and metastatic B16 melanoma. *Am J Pathol* 180 (1) :365–74, 2012, Corresponding Author

169. Kajihara I, Jinnin M, Yamane K, Makino T, Honda N, Igata T, Masuguchi S, Fukushima S, Okamoto Y, Hasegawa M, Fujimoto M, Ihn H. Increased accumulation of extracellular thrombospondin-2 due to low degradation activity stimulates type I collagen expression in scleroderma fibroblasts. *Am J Pathol* 180 (2) :703–14, 2012.

170. Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, Ishiguro N, Ueda-Hayakawa

- I, Asano Y, Ogawa F, Fujikawa K, Miyagi T, Mabuchi E, Hirose K, Akimoto N, Hatta N, Tsutsui K, Higashi A, Igarashi A, Seishima M, Hasegawa M, Takehara K. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. *Arthritis Rheum* 64(2):513-22, 2012
171. Honda N, Jinnin M, Kajihara I, Makino T, Makino K, Masuguchi S, Fukushima S, Okamoto Y, Hasegawa M, Fujimoto M, Ihn H. TGF- $\beta$ -mediated downregulation of microRNA-196a contributes to the constitutive upregulated type I collagen expression in scleroderma dermal fibroblasts. *J Immunol* 188(7):3323-31, 2012.
172. Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, Inokoshi Y, Kawai K, Kanekura T, Habuchi M, Igarashi A, Sogame R, Hashimoto T, Koga T, Nishino A, Ishiguro N, Sugimoto N, Aoki R, Ando N, Abe T, Kanda T, Kuwana M, Takehara K, Fujimoto M. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. *Ann Rheum Dis* 71(5):710-3, 2012
173. Jin G, Matsushita T, Hamaguchi Y, Le Huu D, Ishii T, Hasegawa M, Obata K, Karasuyama H, Takehara K, Fujimoto M. Basophils and mast cells play critical roles for leukocyte recruitment in IgE-mediated cutaneous reverse passive Arthus reaction. *J Dermatol Sci* 67(3):181-9, 2012
174. Nakashima T, Jinnin M, Yamane K, Honda N, Kajihara I, Makino T, Masuguchi S, Fukushima S, Okamoto Y, Hasegawa M, Fujimoto M, Ihn H. Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. *J Immunol* 188(8):3573-83, 2012 .
175. Imura-Kumada S, Hasegawa M, Matsushita T, Hamaguchi Y, Encabo S, Shums Z, Norman GL, Takehara K, Fujimoto M. High prevalence of primary biliary cirrhosis and disease-associated autoantibodies in Japanese patients with systemic sclerosis. *Mod Rheumatol*. 2012 Feb 12 [Epub ahead of print]
176. Hasegawa M, Higashi K, Yokoyama C, Yamamoto F, Tachibana T, Matsushita T, Hamaguchi Y, Saito K, Fujimoto M, Takehara K. Altered expression of dermokine in skin disorders. *J Eur Acad Dermatol Venereol*. 27:867-75, 2013, Corresponding Author
177. Le Huu D, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K, Fujimoto M. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease. *J Invest Dermatol*. 132:2753-61, 2012
- ※178. Okamoto Y, Hasegawa M, Matsushita T, Hamaguchi Y, Huu DL, Iwakura Y, Fujimoto M, Takehara K. Potential roles of interleukin 17A in the development of skin fibrosis. *Arthritis Rheum*. 64(11):3726-3735, 2012, Corresponding Author
179. Wada T, Toga A, Sakakibara Y, Toma T, Hasegawa M, Takehara K, Shigemura T, Agematsu K, Yachie A. Clonal expansion of Epstein-Barr virus (EBV)-infected  $\gamma\delta$  T cells in patients with chronic

- active EBV disease and hydroa vacciniforme-like eruptions. *Int J Hematol*. 96 (4):443-449, 2012
180. Higashi K, Hasegawa M, Yokoyama C, Tachibana T, Mitsui S, Saito K. Dermokine- $\beta$  impairs ERK signaling through direct binding to GRP78. *FEBS Lett*. 586 (16):2300-2305, 2012
181. Hasegawa M, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K. Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis. *Rheumatology (Oxford)*. 52:242-51, 2013, Corresponding Author
182. Hasegawa M, Imura-Kumada S, Matsushita T, Hamaguchi Y, Fujimoto M, Takehara K. Anti-topoisomerase I antibody levels as serum markers of skin sclerosis in systemic sclerosis. *J Dermatol*. 40:89-93, 2013, Corresponding Author
183. Ueda-Hayakawa I, Hasegawa M, Hamaguchi Y, Takehara K, Fujimoto M. Circulating  $\gamma/\delta$  T cells in systemic sclerosis exhibit activated phenotype and enhance gene expression of proalpha2(I) collagen of fibroblasts. *J Dermatol Sci*. 69:54-60, 2013
184. Le Huu D, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K, Tedder TF, Fujimoto M. Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease. *Blood*. 121:3274-83, 2013
185. Huu DL, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K, Fujimoto M. FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin. *Arthritis Rheum*. 65:1624-35, 2013
186. Jin G, Hamaguchi Y, Matsushita T, Hasegawa M, Le Huu D, Ishiura N, Naka K, Hirao A, Takehara K, Fujimoto M. B-cell linker protein expression contributes to controlling allergic and autoimmune diseases by mediating IL-10 production in regulatory B cells. *J Allergy Clin Immunol*. 131(6):1674-82, 2013
187. Hamaguchi Y, Fujimoto M, Matsushita T, Kaji K, Komura K, Hasegawa M, Koderia M, Muroi E, Fujikawa K, Seishima M, Yamada H, Yamada R, Sato S, Takehara K, Kuwana M. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. *PLoS One*. 2013;8(4):e60442.
188. Hasegawa M, Higashi K, Matsushita T, Hamaguchi Y, Saito K, Fujimoto M, Takehara K. Dermokine inhibits ELR(+)-CXCL chemokine expression and delays early skin wound healing. *J Dermatol Sci*. 70:34-41, 2013, Corresponding Author
189. Hasegawa M, Higashi K, Yokoyama C, Yamamoto F, Tachibana T, Matsushita T, Hamaguchi Y, Saito

K, Fujimoto M, Takehara K. Altered expression of dermokine in skin disorders J Eur Acad Derma Venereol. 2013;27(7):867–75. Corresponding Author

190. Hasegawa M, Hatta Y, Matsushita T, Hamaguchi Y, Fujimoto M, Takehara K. Clinical and laboratory features dependent on age at onset in Japanese systemic sclerosis. Mod Rheumatol. 2013;23(5):913–19. Corresponding Author

191. Hamaguchi Y, Matsushita T, Hasegawa M, Ueda-Hayakawa I, Sato S, Takehara K, Fujimoto M. High incidence of pulmonary arterial hypertension in systemic sclerosis patients with anti-centriole autoantibodies Mod Rheumatol. 2013;25(5):798–801.

192. Hasegawa M, Asano Y, Endo H, Fujimoto M, Goto D, Ihn H, Inoue K, Ishikawa O, Kawaguchi Y, Kuwana M, Ogawa F, Takahashi H, Tanaka S, Sato S, Takehara K. Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study. Mod Rheumatol. 2013;23(6):1076–84. Corresponding Author

193. Someya F, Mugii N, Hasegawa M, Yahata T, Nakagawa T. Predictors of exercise-induced oxygen desaturation in systemic sclerosis patients with interstitial lung disease. Respir Care. 2014;59(1):75–80.

194. Hasegawa M, Asano Y, Endo H, Fujimoto M, Goto D, Ihn H, Inoue K, Ishikawa O, Kawaguchi Y, Kuwana M, Ogawa F, Takahashi H, Tanaka S, Sato S, Takehara K. Serum adhesion molecule levels as prognostic markers in patients with early systemic sclerosis: a multicentre, prospective, observational study. PLoS One. 2014;9(2):e88150. Corresponding Author

195. Oishi K, Hamaguchi Y, Matsushita T, Hasegawa M, Okiyama N, Dervedge J, Weinhardt M, Haag R, Tedder TF, Takehara K, Kohsaka H, Fujimoto M. A crucial role of L-selectin in C protein-induced experimental polymyositis of mice. Arthritis Rheumatol. 2014;66(7):1864–71.

196. Kaji K, Fertig N, Medsger TA Jr, Satoh T, Hoshino K, Hamaguchi Y, Hasegawa M, Lucas M, Schnure A, Ogawa F, Sato S, Takehara K, Fujimoto M, Kuwana M. Autoantibodies to RuvBL1 and RuvBL2: A Novel Systemic Sclerosis-Related Antibody Associated With Diffuse Cutaneous and Skeletal Muscle Involvement. Arthritis Care Res (Hoboken). 2014;66(4):575–84.

197. Hatta Y, Hasegawa M, Matsushita T, Hamaguchi Y, Fujimoto M, Takehara K. The clinical characteristics of juvenile-onset systemic sclerosis in Japanese patients. Mod Rheumatol. 2014;24(2):377–79. Corresponding Author

198. Le Huu D, Kimura H, Date M, Hamaguchi Y, Hasegawa M, Hau KT, Fujimoto M, Takehara K, Matsushita T. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease. Blockade of Syk ameliorates the development of murine sclerodermatous chronic

graft-versus-host disease. *J Dermatol Sci*. 2014;74(3):214-21.

199. Oishi K, Hamaguchi Y, Matsushita T, Hasegawa M, Okiyama N, Dervede J, Weinhart M, Haag R, Tedder TF, Takehara K, Kohsaka H, Fujimoto M. A crucial role of L-selectin in C protein-induced experimental polymyositis of mice. *Arthritis Rheumatol*. 2014;66(7):1864-71.

200. Kobayashi T, Hamaguchi Y, Hasegawa M, Fujimoto M, Takehara K, Matsushita T. B cells promote tumor immunity against B16F10 Melanoma. *Am J Pathol*. 2014;184(11):3120-29.

201. Merola JF, Nyberg F, Furukawa F, Goodfield MJ, Hasegawa M, Marinovic B, Szepietowski J, Dutz J, Werth VP. Redefining cutaneous lupus erythematosus: a proposed international consensus approach and results of a preliminary questionnaire. *Lupus Sci Med*. 2015;2(1):e000085.

202. Hamaguchi Y, Koderu M, Matsushita T, Hasegawa M, Inaba Y, Usuda T, Kuwana M, Takehara K, Fujimoto M. Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies. *Arthritis Rheumatol*. 2015;67(4):1045-52.

203. Matsushita T, Hamaguchi Y, Hasegawa M, Takehara K, Fujimoto M. Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity. *Rheumatology(Oxford)*. 2016;55(2):263-67.

204. Matsushita T, Le Huu D, Kobayashi T, Hamaguchi Y, Hasegawa M, Naka K, Hirao A, Muramatsu M, Takehara K, Fujimoto M. A novel splenic B1 regulatory cell subset suppresses allergic disease through phosphatidylinositol 3-kinase-Akt pathway activation. *J Allergy Clin Immunol*. 2016:S0091-6749(16)00130-5.